v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (4,331,947) $ (1,485,228)
Adjustments to reconcile net loss to net cash used in operating activities:    
Change in operating lease right-of-use assets 230,255
Stock-based compensation expense 704,407 367,737
Common stock issued for services 53,400
Changes in operating assets and liabilities:    
Prepaid insurance (29,706) 6,301
Other prepaid expenses (27,663) (2,290)
Accounts payable and accrued expenses (108,592) 36,443
Research and development contract liabilities (796) 21,069
Operating lease liabilities 67,418
Net cash used in operating activities (3,443,224) (1,055,968)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Capitalized costs LiGHT proton therapy system equipment (24,859)  
Note receivable Nomad Transportable Power Systems (6,500,000)
Net cash used in investing activities (6,524,859)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from sale of securities in registered direct offerings, net of offering costs 16,433,526 914,228
Payment of deferred offering costs (10,000)
Exercise of common stock warrants 1,097,828
Net cash provided by financing activities 17,531,354 904,228
NET CHANGE IN CASH    
Net increase (decrease) 7,563,271 (151,740)
Cash - Beginning of period 5,106,872 1,038,952
Cash - End of period 12,670,143 887,212
Supplemental disclosures of cash flow information:    
Cash paid for interest 4,945
Non-cash investing and financing activities:    
Settlement of accrued compensation to Board of Directors by issuance of stock options 27,500
Exercise of pre-funded warrants 61
Conversion of Series B Convertible Preferred Stock into common stock and related dividend 1,800,642
Conversion of Series A Convertible Preferred Stock into common stock 3,500,000
Accrual of deferred offering costs $ 188,826